|Articles|February 12, 2008
Altus CEO Resigns
Author(s)BioPharm International Editors
Sheldon Berkle has resigned as president, chief executive officer, and member of the board of directors of Altus Pharmaceuticals, Inc. (Cambridge, MA).
Advertisement
Sheldon Berkle has resigned as president, chief executive officer, and member of the board of directors of Altus Pharmaceuticals, Inc. (Cambridge, MA). David D. Pendergast, PhD, has been appointed to the interim position of executive chairman while the company initiates a search for a new president and chief executive officer.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
5